Goldman Sachs Increases Stake in Mayne Pharma Group

Mayne Pharma Group ( (AU:MYX) ) has provided an announcement.

Goldman Sachs Group, Inc. has increased its voting power in Mayne Pharma Group Limited from 6.14% to 7.54%, as indicated in a recent notice of change of interests of a substantial holder. This change reflects a significant shift in the ownership structure of Mayne Pharma, potentially impacting the company’s governance and strategic direction, and signaling increased confidence from a major financial institution.

The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

Mayne Pharma Group Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of branded and generic pharmaceuticals. The company is known for its diverse range of products that cater to various therapeutic areas, with a market focus on both domestic and international markets.

YTD Price Performance: -3.02%

Average Trading Volume: 908,519

Technical Sentiment Signal: Sell

Current Market Cap: A$391.6M

Find detailed analytics on MYX stock on TipRanks’ Stock Analysis page.